Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

69°
- Benton, AR (72018)
  Today
  
  Mixed clouds and sun with scattered thunderstorms. High 72F. Winds S at 10 to 20 mph. Chance of rain 50%..
  
  Tonight
  
  Rain showers this evening with overcast skies overnight. Thunder possible. Low 52F. Winds SW at 10 to 15 mph. Chance of rain 40%.
  
  Updated: January 8, 2026 @ 1:18 pm
- Full Forecast

- Site search

Home
News
- Local News
Sports
Obituaries
Multimedia
- Photo Galleries
- Videos
e-Edition
Classifieds
Archives
Readers Choice 2025

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Atea Pharmaceuticals, Inc. - common stock (NQ:AVIR)

3.615 +0.135 (+3.88%)

Streaming Delayed Price Updated: 2:48 PM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Atea Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 6 7 8 Next >

Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024

April 29, 2024

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

March 27, 2024

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Recap: Atea Pharmaceuticals Q4 Earnings ↗

February 28, 2024

Via Benzinga

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

February 28, 2024

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals Earnings Preview ↗

February 27, 2024

Via Benzinga

Atea Pharmaceuticals's Earnings Outlook ↗

November 07, 2023

Via Benzinga

Earnings Preview For Atea Pharmaceuticals ↗

August 07, 2023

Via Benzinga

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024

February 21, 2024

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals' Hepatitis C Virus Candidate Shows Efficacy ↗

January 09, 2024

Atea Pharmaceuticals Inc (NASDAQ: AVIR) reported initial data from the first 52 patients in the lead-in cohort of its Phase 2 combination eight-week study of bemnifosbuvir and ruzasvir (RZR) for

Via Benzinga

Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19

January 08, 2024

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 03, 2024

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023

November 13, 2023

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

November 08, 2023

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences

November 08, 2023

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023

November 02, 2023

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023

November 01, 2023

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis

October 23, 2023

Via ACCESSWIRE

Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

September 06, 2023

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023 ↗

August 10, 2023

Via Benzinga

Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

August 08, 2023

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023

August 01, 2023

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination

June 15, 2023

Combination Offers Opportunity to Improve Standard of Care with Potential for Short Duration, Protease Inhibitor-Free Treatment

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference

June 05, 2023

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Skyline Champion, Atea Pharmaceuticals And Other Big Stocks Moving Lower On Tuesday ↗

May 30, 2023

U.S. stocks traded mixed, with the Dow Jones dropping over 100 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Atea Pharmaceuticals’ Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences

May 30, 2023

Proposal Fundamentally Undervalues Atea; Not in the Best Interests of Atea or Its Shareholders

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Why Nvidia Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 30, 2023

Gainers QualTek Services Inc. (NASDAQ: QTEK) shares jumped 127.2% to $0.1740 after dropping around 21% on Friday. Qualtek Services recently filed voluntarily petitions for Chapter 11 bankruptcy.

Via Benzinga

Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences

May 23, 2023

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Biotech Bargain Hunt: Concentra Biosciences Eyes Atea's Promising COVID-19 Response ↗

May 22, 2023

Earlier today, Concentra Biosciences, an affiliate of Tang Capital, sent an acquisition proposal to Atea Pharmaceuticals Inc (NASDAQ: AVIR) at $5.75 per share, representing a 55% premium to Friday’s...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

May 22, 2023

Via Benzinga

Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

May 22, 2023

Gainers Greenhill & Co., Inc. (NYSE: GHL) shares jumped 116.4% to $14.67 after Mizuho announced it would acquire the company for $15 per share.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Entertainment
Local Events
Obituaries
Multimedia
Announcements
e-Edition
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

bentoncourier.com
321 North Market Street
Benton, AR 72018
Phone: 501-315-8228
Email: bcadmin@bentoncourier.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Benton, AR (72018)

Today

Tonight

Atea Pharmaceuticals, Inc. - common stock (NQ:AVIR)

All News about Atea Pharmaceuticals, Inc. - common stock

Sections

Services

Follow Us